The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2025 | CAR-T in Tübingen University Hospital: manufacturing, post-treatment monitoring, and more
In this video, Jan Schröder, MD, Tübingen University Hospital, Tübingen, Germany, comments on the work being done in the field of CAR T-cell therapy in his center, the Tübingen University Hospital. Dr Schröder highlights the efforts to advance the treatment for patients not eligible for commercial CAR-T products and improve post-treatment monitoring by tracking IgG levels and T-cell reconstitution, aiming to predict and manage infectious complications. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In our center, we actually have the interesting situation that we are manufacturing our own CD19 CAR T-cells, but also other CAR-T products. So we have been trying to advance this treatment for patients who are not so far eligible for a commercial product. This may include refractory ALL and DLBCL patients where, for example, we deployed successfully CD19, CD22 CAR-T self-manufactured product for a patient with a highly refractory ALL and a lengthy course that was published in JAMA Oncology last year...
In our center, we actually have the interesting situation that we are manufacturing our own CD19 CAR T-cells, but also other CAR-T products. So we have been trying to advance this treatment for patients who are not so far eligible for a commercial product. This may include refractory ALL and DLBCL patients where, for example, we deployed successfully CD19, CD22 CAR-T self-manufactured product for a patient with a highly refractory ALL and a lengthy course that was published in JAMA Oncology last year.
The other area where we are very active, together with collaborators from Mitanni and in Erlangen, is to pursue CD19 CAR-T therapy for rheumatological diseases, especially in Tübingen in systemic sclerosis.
And another project that we are working on, is just improving the post-treatment monitoring. In CAR-T, we know that the highest treatment-induced morbidity and mortality actually comes from infection-related morbidity and mortality that is related to the immune deficiency, the B-cell deficiency, that you induce. We have a very well-annotated data set that we are now submitting that has actually been accepted last week, where we see that closely following the patients with regard to their IgG levels and their T-cell reconstitution is really a good predictor of how to manage and monitor infectious complications.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
